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Correlation between Metabolic Syndrome and Lower Urinary Tract 
Symptoms of Males and Females in the Aspect of Gender-Specific 
Medicine: A Single Institutional Study
Geun Sik Hong, Bong Suk Shim, Woo Sik Chung, Hana Yoon
Department of Urology, Ewha Womans University School of Medicine, Seoul, Korea 
Purpose: We attempted to examine the correlation between metabolic syndrome and 
lower urinary tract symptoms (LUTS) in the aspect of gender-specific medicine.   
Materials and Methods: A total of 922 patients participating in a health examination 
completed the International Prostate Symptom Score (IPSS) questionnaire and the 
Overactive Bladder Questionnaire Short Form (OABq-SF) symptom bother scale from 
March 2008 to July 2009. Metabolic syndrome was defined by using the National 
Cholesterol Education Program Adult Treatment Panel III criteria announced in 2001. 
We analyzed differences in lower urinary tract symptoms according to the presence of 
metabolic syndrome and the component elements of metabolic syndrome.  
Results: The subjects were 538 males and 384 females with a mean age of 48.8±6.8 years. 
Among all patients, the number of patients with metabolic syndrome was 143 (15.5%); 
there were 110 males (20.4%) and 33 females (8.6%), showing a significant difference. 
There were no differences in scores on the IPSS or OABq-SF with respect to the presence 
or absence of metabolic syndrome in males. In females, however, there were significant 
differences in the IPSS and OABq-SF depending on the presence or absence of metabolic 
syndrome. In males and females, the IPSS total score was significantly correlated with 
age. Also, high-density lipoprotein (HDL) cholesterol in males and triglyceride in fe-
males was significantly correlated with the IPSS total score.   
Conclusions: There are sex differences in the morbidity rate of metabolic syndrome and 
its effect on lower urinary tract symptoms. Therefore, it is necessary to consider gen-
der-specific medicine in the diagnosis and treatment of LUTS.    
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INTRODUCTION
Gender-specific medicine is a medical methodology in 
which the gender differences between males and females 
are recognized and actively utilized in medical research, di-
agnosis, and treatment as well as in education. Gender- 
specific medicine assumes that gender is an important fac-
tor in the pathogenesis, disease progression, risk, and prog-
nosis of many known diseases. According to gender-specific 
medicine, the management of certain diseases should be 
specified on the basis of a patient’s gender, because males 
and females have different drug responses, risk factors, 
and prognoses.
Increasing evidence from clinical and epidemiological 
studies has shown associations between lower urinary 
tract symptoms (LUTS) and major chronic illnesses, such 
as heart disease and diabetes as well as related lifestyle fac-
tors, and these associations have motivated interest in the 
contribution of factors outside the urinary tract to uro-
logical symptoms-the so-called “beyond the bladder” hy-
pothesis [1-4]. 
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TABLE 1. Comparison of the prevalence rate of metabolic 
syndrome in males and females
Men Women Total
Presence of MS 110 (20.4%)   33 (8.6%) 143 (15.5%)
Absence of MS 438 351 789
Total 538 384 922
MS: metabolic syndrome
TABLE 2. IPSS comparison according to the presence or absence
of metabolic syndrome in males
IPSS MS group Non-MS group p-value
    1 0.73±0.08 0.75±0.05 0.329
    2 0.71±0.07 0.87±0.04 0.443
    3 0.75±0.10 0.81±0.05 　0.710
    4 0.56±0.08 0.56±0.04 　0.665
    5 0.90±0.10 1.04±0.05 　0.282
    6 0.55±0.09 0.59±0.04 　0.719
    7 0.80±0.10 0.75±0.05 　0.279
Total 5.03±0.46 5.40±0.27 0.399
IPSS: International Prostate Symptom Score, MS: metabolic syn-
drome
TABLE 3. Comparison of OABq-SF depending on the presence or
absence of metabolic syndrome in males 
OABq-SF MS group Non-MS group p-value
1 1.37±0.55 1.41±0.04 0.350
2 1.22±0.05 1.29±0.05 0.341
3 1.25±0.06 1.26±0.32 0.946
4 1.31±0.58 1.45±0.04 0.119
5 1.47±0.69 1.54±0.43 0.478
6 1.14±0.04 1.22±0.03 0.203
OABq-SF: Overactive Bladder Questionnaire Short Form, MS: 
metabolic syndrome
Adult Treatment Panel III (NCEP-ATP III) show a rela-
tionship between markers of metabolic syndrome and 
LUTS defined as having 3 of 4 urinary symptoms (nocturia, 
incomplete bladder emptying, weak stream, and hesitancy) 
[4]. Some symptoms, such as incontinence in women and 
nocturia in both men and women, have been associated with 
higher levels of bother or treatment seeking or both [5-7].
This study examined the correlations between metabolic 
syndrome and LUTS according to male and female gender 
in the aspect of gender-specific medicine. 
MATERIALS AND METHODS
A total of 922 subjects who had participated in general 
health examinations at our hospital from March 2008 to 
July 2009 completed a general health examination ques-
tionnaire, the International Prostate Symptom Score (IPSS) 
questionnaire [8], and the Overactive Bladder Questio-
nnaire Short Form (OABq-SF) symptom bother scale [9]. 
　This study excluded cases that had been diagnosed with 
or administered a drug for a urologic disease. The diag-
nostic criteria for metabolic syndrome had to satisfy three 
or more of the NCEP-ATP III criteria, which are as follows: 
1) hypertension (systolic blood pressure of 130 mmHg or 
higher or diastolic blood pressure of 85 mmHg or higher), 
2) hyperglycemia (fasting blood sugar level of 110 mg/dl or 
higher), 3) obesity (waist circumference of 80 cm or greater 
or body mass index of 25 kg/m
2 or heavier), 4) hypo-HDL- 
cholesterolemia of less than 50 mg/dl, and 5) hypertrigly-
ceridemia of 150 mg/dl or higher.   
The chi-square test, t-test, or multiple linear regression 
test was used to analyze 1) differences in the prevalence of 
metabolic syndrome of males and females, 2) differences 
in each component element of the IPSS and OABq-SF de-
pending on the presence or absence of metabolic syndrome 
in males and females, and 3) correlations between A) age 
and IPSS total score, and B) component elements of meta-
bolic syndrome and IPSS total score. All analyses were per-
formed by using the SPSS program version 12.0 for 
Windows. In all comparisons of values, p-values less than 
0.05 were considered to be statistically significant. 
RESULTS
Analysis was conducted on a total of 922 subjects, of whom 
538 were males and 384 were females with a mean age of 
48.8±6.8 years (males, 48.8±6.2 years old; females, 48.9±7.6 
years old). A total of 143 (15.5%) subjects satisfied the diag-
nostic criteria for metabolic syndrome, of whom 110 were 
males (20.4%) and 33 were females (8.6%), showing a sig-
nificant difference (p＜0.005) (Table 1).
　Male subjects were divided into two groups: a group with-
out metabolic syndrome (428 subjects) and a group with meta-
bolic syndrome (110 subjects). The differences in IPSS and 
OABq-SF depending on the presence or absence of metabol-
ic syndrome were examined. There were no significances 
in either the IPSS (Table 2) or the OABq-SF (Table 3). 
　On the contrary, when the female patients were divided 
into a group without metabolic syndrome (351 subjects) and 
a group with metabolic syndrome (33 subjects), the differ-
ences in the IPSS and OABq-SF between these groups were 
found to be statistically significant. Of seven items and the 
total score for the IPSS, depending on the presence or ab-
sence of metabolic syndrome, significant differences were 
found in six items and the total score, which were as follows: 
incomplete emptying (p=0.002), frequency (p=0.012), ur-
gency (p＜0.001), weak stream (p=0.031), straining (p= 
0.021), nocturia (p＜0.001), and total score (p＜0.001) (Table 
4). Also, of six items on the OABq-SF, depending on the pres-
ence or absence of metabolic syndrome, significant differ-
ences were found in five items, which were as follows: 1) un-
comfortable urge to urinate (p＜0.001), 2) sudden urge to 
urinate with little or no warning (p＜0.001), 3) accidental 
loss of small amounts of urine (p＜0.001), 4) nighttime uri-
nation (p=0.043), and 5) waking up at night because you had Korean J Urol 2010;51:631-635
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TABLE 4. IPSS comparison according to the presence or absence 
of metabolic syndrome in females
IPSS MS group Non-MS group p-value
    1 0.85±0.21 0.40±0.04 0.002
a
    2 1.27±0.20 0.82±0.05 0.012
a
    3 0.81±0.21 0.55±0.05 　0.108
    4 0.97±0.22 0.45±0.04 　＜0.001
a
    5 0.96±0.21 0.58±0.05 　0.031
a
    6 0.61±0.16 0.30±0.04 　0.021
a
    7 1.48±0.22 0.79±0.06 　＜0.001
a
Total 6.97±1.21 3.90±0.23 ＜0.001
a
IPSS: International Prostate Symptom Score, MS: metabolic syn-
drome, 
a: statistically significant
TABLE 5. Comparison of OABq-SF depending on the presence or
absence of metabolic syndrome in females 
OABq-SF MS group Non-MS group p-value
1 1.91±0.23 1.49±0.04 ＜0.001
a
2 1.70±0.20 1.28±0.05 ＜0.001
a
3 1.76±0.23 1.40±0.04 ＜0.001
a
4 1.93±0.19 1.48±0.05 0.043
a
5 2.09±0.16 1.62±0.05 0.006
a
6 1.36±0.18 1.20±0.03 0.126
OABq-SF: Overactive Bladder Questionnaire Short Form, MS: 
metabolic syndrome, 
a: statistically significant
TABLE 6. Correlation between IPSS total score
a and age or components of metabolic syndrome in males and females
Male Female
Beta Std. error p-value Beta Std. error p-value
Age
a 0.253 ＜0.001 ＜0.001
b 0.150 ＜0.001 0.007
b
BMI
a −0.019 0.092 0.690 −0.033 0.103 0.573
SBP
a 0.013 0.028 0.850 −0.033 0.031 0.737
DBP
a −0.081 0.037 0.361 0.020 0.045 0.830
TG
a 0.008 0.003 0.537 0.139 0.006 0.021
b b b
HDL-C
a −0.020 0.013 0.033
b −0.054 0.022 0.338
Glucose
a −0.003 0.025 0.642 −0.001 0.023 0.985
IPSS: International Prostate Symptom Score, Std. error: standard error, BMI: body mass index, SBP: systolic blood pressure, DBP:
diastolic blood pressure, TG: triglyceride, HDL-C: High-density lipoprotein cholesterol, 
a: continuous variable, 
b: statistically significant
to urinate (p=0.006) (Table 5).
As such, there were no differences in LUTS with respect 
to the presence or absence of metabolic syndrome in male 
subjects, whereas significant differences were found in 
LUTS depending on the presence or absence of metabolic 
syndrome in females.  
In order to find which component of metabolic syndrome 
affects voiding symptoms, we investigated correlations be-
tween 1) age and component elements of the diagnostic cri-
teria of metabolic syndrome and 2) IPSS total score for men 
and women. Multiple regression analysis was performed 
for age and components of metabolic syndrome [systolic 
and diastolic blood pressure (BP), blood glucose, trigly-
ceride, high-density lipoprotein (HDL) cholesterol, and 
body mass index (BMI)] and the total score on the IPSS in 
males and females. There were significant correlations be-
tween age and the IPSS total score in both males (p＜0.001) 
and females (p=0.007). In addition, significant correlations 
between HDL cholesterol and the IPSS total score in males 
were found (p=0.033). In females, however, significant cor-
relations were found between triglyceride and the IPSS to-
tal score (p=0.021) (Table 6).
DISCUSSION
Metabolic syndrome is a cluster of disorders associated 
with the development and mortality of cardiovascular dis-
ease with a common feature of insulin resistance. Patients 
with metabolic syndrome are twice as likely to have car-
diovascular disease and four times as likely to have type 
II diabetes mellitus as are patients without metabolic 
syndrome. The mortality rate due to cardiovascular or coro-
nary arterial diseases is also increased 2.9 to 4.0 times in 
patients with metabolic syndrome [10-12].    
The prevalence rate of metabolic syndrome in the United 
States has a diverse range, showing figures from 2.4% to 
43.5%. In this country, a high morbidity rate of 21.5% was 
shown in a population of patients with an age of 20 years 
old or older [13]. This study also showed a similar result 
with a prevalence rate of 15.5%. 
One study reported that Asian women have a higher 
prevalence of the metabolic syndrome than do Asian men 
[14]. However, this study showed a prevalence rate of 
20.4% for males and of 8.6% for females, showing a higher 
prevalence for males. 
Geer and Shen discussed the gender differences ob-
served in body composition with regard to adiposity and in-
sulin resistance [15]. In men, greater visceral fat and ele-
vated fat content in the liver are most likely due to the ab-
sence of the protective effect of estrogen, which is found in 
premenopausal women. This absence leads to increased in-
sulin resistance in individuals with increased visceral 
adiposity. Compared with men, premenopausal women 
are protected from cardiovascular disease. However, once Korean J Urol 2010;51:631-635
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postmenopausal, women rapidly catch up [15]. The high 
prevalence rate of males in this study was due to the rela-
tively high proportion of premenopausal women.  
The basic pathophysiology of metabolic syndrome is 
known to be hyperinsulinism developed secondarily from 
insulin resistance due to insulin-mediated glucose absorp-
tion disorder [16-18]. Insulin resistance or hyperinsulinism 
affects the ventromedial nucleus, which regulates the acti-
vation of the sympathetic nervous system of the hypotha-
lamus. It increases blood and tissue catecholamines, stim-
ulates the peripheral sympathetic nervous system, and in-
creases the activity of the sympathetic nervous system. 
Accordingly, the prostate or bladder neck, which has a wide 
distribution of the sympathetic system, also becomes sti-
mulated and LUTS may be manifested [19].     
In this study, there was no difference in LUTS in males 
depending on the presence or absence of metabolic syn-
drome. However, there were statistically significant differ-
ences for most items in females.   
Several studies have suggested a relationship between 
voiding symptoms and the presence of the metabolic syn-
drome [2,4]. Rohrmann et al, in a large population-based 
survey, found that the components of the metabolic syn-
drome were likely to be associated with LUTS in older men 
and, recently, in a population-based sample of African- 
American men aged 40-79 years [4].
However, Temml et al reported that the metabolic syn-
drome was not associated with IPSS, the IPSS obstructive 
or irritative subscore, or LUTS. The proportion of LUTS 
and the mean IPSS did not differ significantly regarding 
the presence or absence of the metabolic syndrome in either 
sex [20]. Park et al reported that no significant differences 
were found in the mean IPSS or quality-of-life score be-
tween men with or without the metabolic syndrome [21].
The pathogenesis of LUTS is currently considered to be 
a sex-independent, multifactorial process with the involve-
ment of structural changes in the urinary bladder, in-
fection, comorbidity, medication, neurologic factors, and 
hormones [20]. Kupelian et al reported statistically sig-
nificant associations between urological symptoms and 
type 2 diabetes or increased blood sugar [22].
One study suggested that vascular risk factors play a role 
in the development of LUTS in both sexes [23]. In that 
study, the IPSS was identical in men with 0 (6.2±4.1) and 
1 (6.2±4.4) vascular risk factor, yet increased to 7.7±5.5 in 
those with ≥2 risk factors (p=0.01). In women, the IPSS 
increased from 4.8±4.6 in those with no vascular risk factors 
to 5.7±5.3 (＋18.7%) in those with 1 and to 7.0±5.7 (＋45.8%) 
in those with ≥2 factors (p=0.05).
In our study, we found significant correlations between 
HDL cholesterol and the total score on the IPSS in males 
(p=0.033). In females, significant correlations were found 
between triglyceride and the IPSS total score (p=0.021) 
(Table 6). Park et al also reported that hypertrigly-
ceridemia is associated with moderate to severe LUTS in 
men [21].
In 1997, Legato, a cardiologist at Columbia Medical 
School, asserted that the recognition of gender differences 
was very important in medical research and medical treat-
ment and established a new medical concept called “gender- 
specific medicine” in which differences between males and 
females are researched [24]. Programs of gender difference 
and gender-specific education at medical centers and medi-
cal schools that apply the concept of gender difference in 
medical treatment are rapidly increasing. 
Men and women differ in bone, cardiovascular system, 
brain, pain, immune system, lung, and especially the uro-
genital system. Gender-specific medicine still means wom-
en’s health to all but the indoctrinated few, and many con-
tinue to view women’s health as a feminist, commercial, or 
boutique issue more suited to marketing teams for hospital 
centers than to serious practitioners of medicine [24].  In 
the future, studies in gender-specific medicine may become 
vigorous in areas such as pharmacologic action of drugs; 
chromosomal body and genetic substance; hormones and 
the endocrine system, for which male and female differ-
ences are typically distinctive; adjustment of the biological 
function of the nervous system; various infections and de-
generative diseases; metabolic diseases; tumors; psychiatric 
medicine; behavior; studies on emotion; environmental 
medicine; public health; and medical ethics.   
The necessity of gender-specific medicine will be in-
evitable in the study of metabolic syndrome and in the diag-
nosis and treatment of LUTS, as dealt with in this study. 
Furthermore, metabolic syndrome has a different morbid-
ity rate for males and females and its correlation with 
LUTS may also differ in males and females. Thus, gender 
differences must be considered in the prevention or treat-
ment of LUTS in patients with metabolic syndrome. The 
importance of gender-specific medicine in such areas will 
be significant, and further study on this issue is needed.  
Finally, there is a limitation to our study. Because this 
study consisted of a single institution in a metropolitan 
area, there may be a potential selection bias. Thus, our 
study represents a specific class of patients.
CONCLUSIONS
The proportion of metabolic syndrome was higher in 
males. In males, there were no significant differences in 
LUTS depending on the presence or absence of metabolic 
syndrome, whereas differences in LUTS secondary to the 
presence or absence of metabolic syndrome may be seen in 
females. However, a study with participants selected from 
a larger area may be necessary.   
In view of gender-specific medicine, which has recently 
come into focus, the morbidity rate of metabolic syndrome 
and its effect on LUTS may differ depending on gender. 
Therefore, such aspects must be considered in the estab-
lishment of a treatment policy.  
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